Core Viewpoint - Growth investors are focused on stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to their inherent risks and volatility [1] Company Summary - ANI Pharmaceuticals (ANIP) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 2%, but projected EPS growth for this year is expected to be 22.2%, surpassing the industry average of 15.3% [4] - ANI's year-over-year cash flow growth is currently at 22.1%, significantly higher than the industry average of -4.4% [5] - The annualized cash flow growth rate for ANI over the past 3-5 years is 10.4%, compared to the industry average of 3.4% [6] - Current-year earnings estimates for ANI have been revised upward, with the Zacks Consensus Estimate increasing by 1.2% over the past month [7] - ANI has achieved a Growth Score of B and a Zacks Rank 1, indicating it is a potential outperformer and a solid choice for growth investors [9]

Core Insights - ANI Pharmaceuticals, Inc. will release its first quarter 2025 financial results on May 9, 2025, before the market opens [1] - A conference call will be hosted by key executives to discuss the results, scheduled for 8:00 a.m. ET on the same day [1] Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [2] - The company aims for sustainable growth through its Rare Disease business, which includes products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology [2] - ANI also has a Generics business that leverages R&D expertise and U.S.-based manufacturing, along with a Brands business [2]

Group 1: Market Context - President Donald Trump's recently imposed tariff is causing volatility in the equity market, impacting the slowing domestic economy by increasing prices of both domestic and imported goods, which fuels uncertainty [1] - A curated portfolio of low-beta stocks is recommended as a strategy to safeguard against market uncertainty, allowing investors to navigate volatility with greater resilience [1] Group 2: Stock Recommendations - Stocks such as ANI Pharmaceuticals, Inc. (ANIP), Expand Energy Corporation (EXE), Avista Corp (AVA), and Contango ORE, Inc. (CTGO) are highlighted as potential investment opportunities [2] Group 3: Stock Characteristics - Beta measures the volatility of a stock compared to the market, with a beta of 1 indicating movement with the market, greater than 1 indicating higher volatility, and less than 1 indicating lower volatility [3][4] - A screening criterion for low-beta stocks includes a beta between 0 and 0.6, ensuring less volatility than the market [5] - Additional criteria for stock selection include positive price movement over the last month, average 20-day volume greater than 50,000, a minimum price of $5, and a Zacks Rank of 1 (Strong Buy) [6] Group 4: Company Insights - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on affordable quality medicines, recently launching Nitazoxanide Tablets, with upward revisions to earnings estimates for 2025 [7] - Expand Energy, a natural gas producer, is benefiting from increasing demand for clean energy and is on track to meet a $500 million synergy target, with upward earnings estimate revisions for 2025 and 2026 [8] - Avista Corp is a leading utility with low carbon emissions, planning to increase its capital investment from an estimated $525 million in 2025 to $650 million in 2029, with a projected rate base growth of 5% to 6% and upward earnings estimate revisions for 2025 [9] - Contango ORE, a gold explorer, is seeing increased net operating cash flows due to production commencement at Manh Choh, with a significant portion of net gold production linked to spot gold prices for fiscal years 2025 and 2026 [10]

Group 1 - The stock of ANI Pharmaceuticals, Inc. (ANIP) is experiencing significant attention due to high implied volatility in the options market, particularly the Apr 17, 2025 $75.00 Put option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - ANI Pharmaceuticals holds a Zacks Rank 1 (Strong Buy) in the Medical - Biomedical and Genetics industry, which is in the top 29% of the Zacks Industry Rank, indicating strong analyst sentiment [3] Group 2 - Over the past 60 days, two analysts have raised their earnings estimates for ANI Pharmaceuticals for the current quarter, increasing the Zacks Consensus Estimate from $1.09 to $1.37 per share [3] - The high implied volatility may present trading opportunities, as seasoned options traders often seek to sell premium on options with elevated implied volatility, aiming to benefit from time decay [4]

Market Overview - The U.S. stock market experienced significant volatility in Q1 2025, with the S&P 500 recording its largest quarterly loss in nearly three years, declining by 4.6% and ending a five-quarter winning streak [1] - Investor sentiment was negatively impacted by President Trump's aggressive tariff policies, raising concerns about a potential global trade war and economic growth [1] - Inflation concerns and fluctuations in consumer sentiment contributed to increased market volatility, leading analysts to raise recession odds and adjust projections [1] Investment Opportunities - Despite market challenges, there are opportunities for investors, particularly in stocks that demonstrate relative price strength, which can provide stability during turbulent times [2] - Companies with strong fundamentals that outperform broader market downturns are highlighted as potential candidates for investment [2] Recommended Stocks - IHS Holding Limited (IHS): Market cap of $1.8 billion, with a Zacks Consensus Estimate indicating 114.7% earnings growth for 2025 and a VGM Score of A. Shares have increased by 50.7% over the past year [10][11] - ANI Pharmaceuticals, Inc. (ANIP): Market cap of $1.2 billion, with a Zacks Consensus Estimate indicating 22.1% earnings growth for 2025. The company has a trailing four-quarter earnings surprise of approximately 17.3% and shares have declined by 1.4% in the past year [11][12] - Pediatrix Medical Group (MD): Market cap of $1.2 billion, with a Zacks Consensus Estimate indicating 5.4% earnings growth for 2025 and a VGM Score of A. Shares have risen by 47.4% in the past year [13][14] - Fresenius Medical Care AG (FMS): Market cap not specified, with a Zacks Consensus Estimate indicating 25.9% earnings growth for 2025 and a trailing four-quarter earnings surprise of approximately 15.7%. Shares have increased by 29.1% in the past year [15][16] - LendingTree (TREE): Market cap of $688.6 million, with a Zacks Consensus Estimate indicating 22.9% earnings growth for 2025 and a VGM Score of A. Shares have risen by 19.7% in the past year [16][17] Screening Parameters - Stocks selected based on relative price strength must show positive relative price changes over 12 weeks, 4 weeks, and 1 week, as well as positive current-quarter estimate revisions over the last four weeks [8] - Only Zacks Rank 1 (Strong Buy) stocks that have historically outperformed the S&P 500 are considered, with a minimum price of $5 and an average 20-day volume of at least 50,000 to ensure liquidity [9]

Market Overview - The S&P 500 index declined over 5% in Q1 2025 due to concerns over tariffs, economic uncertainty, and the rise of low-cost AI offerings in China, leading to heightened market volatility [1] - Goldman Sachs has lowered its year-end S&P 500 target, citing increased recession risks and expectations of weakening corporate profits [1] Value Investing Strategy - Focusing on undervalued stocks with strong fundamentals can provide a buffer against market downturns and potential upside when market sentiment shifts [2] - Value stocks tend to perform well when growth stocks face challenges, making them appealing for risk-averse investors during turbulent times [2] Earnings Yield Metric - Earnings Yield is calculated as annual earnings per share (EPS) divided by market price, serving as a measure of anticipated return from earnings for each dollar invested [4] - A higher earnings yield indicates a stock is undervalued compared to those with lower yields, which are seen as overpriced [4] - The earnings yield can be compared to prevailing interest rates, such as the 10-year Treasury yield, to assess relative value against risk-free returns [5][6] Stock Screening Criteria - A primary screening criterion is an Earnings Yield greater than 10%, supplemented by estimated EPS growth for the next 12 months being greater than or equal to the S&P 500 [7] - Additional criteria include an average daily trading volume of at least 100,000 and a current price of $5 or more [8][9] Selected Value Stocks - ANI Pharmaceuticals (ANIP): Expected EPS growth of 22% and 14% for 2025 and 2026, respectively, with a Zacks Rank 1 and Value Score of B [10] - Insteel Industries (IIIN): Projected EPS growth of 39.4% and 116% for fiscal 2025 and 2026, respectively, also with a Zacks Rank 1 and Value Score of B [11] - Pitney Bowes (PBI): Anticipated EPS growth of 47.5% and 8.3% for 2025 and 2026, with a Zacks Rank 1 and Value Score of A [12] - IHS Holding (IHS): Expected EPS growth of 115% and 17% for 2025 and 2026, holding a Zacks Rank 1 and Value Score of A [13] - HighPeak Energy (HPK): Projected EPS growth of 157% and 20% for 2025 and 2026, with a Zacks Rank 1 and Value Score of A [14]

PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows: Date: Thursday, April 3, 2025 Time: 7:45am ET Webcast: Click here The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events an ...

Wall Street is suffering from volatility in the first quarter of 2025. Out of the three large-cap indexes, the S&P 500 and the Nasdaq Composite are in negative territory year to date, while the Dow has remained almost flat. The small-cap benchmarks — the Russell 2000 and the S&P 600 — are also in the negative zone year to date. Similarly, the mid-cap-specific S&P 400 index is also in the red.Despite this headwind, a handful of mid-cap stocks with a top Zacks Rank is set for solid returns in the short term. ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

Core Insights - ANI Pharmaceuticals, Inc. (ANIP) has reached a significant support level, indicating a potential investment opportunity from a technical perspective [1] - The recent breakout of ANIP's 50-day simple moving average above its 200-day moving average signifies a "golden cross," which is a bullish indicator [1] - Over the past four weeks, ANIP's stock has gained 10.9%, and it currently holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting a potential breakout [3] Technical Analysis - A golden cross consists of three stages: a downtrend that bottoms out, a shorter moving average crossing above a longer moving average, and continued upward momentum [2] - The golden cross is contrasted with a death cross, which indicates potential bearish price movement [2] Earnings Outlook - ANIP's positive earnings outlook for the current quarter strengthens the bullish case, with no earnings estimates decreasing in the past two months and three revisions higher [3] - The Zacks Consensus Estimate for ANIP has also increased, further supporting the positive sentiment around the stock [3][4]